dc.creatorRosso, Marina
dc.creatorLapyckyj, Lara
dc.creatorAmiano, Nicolás Oscar
dc.creatorBesso, María José
dc.creatorSanchez, Mercedes Leonor
dc.creatorChuluyan, Hector Eduardo
dc.creatorVazquez, Monica Hebe
dc.date.accessioned2017-03-22T14:35:33Z
dc.date.accessioned2018-11-06T11:32:28Z
dc.date.available2017-03-22T14:35:33Z
dc.date.available2018-11-06T11:32:28Z
dc.date.created2017-03-22T14:35:33Z
dc.date.issued2014-09
dc.identifierRosso, Marina; Lapyckyj, Lara; Amiano, Nicolás Oscar; Besso, María José; Sanchez, Mercedes Leonor; et al.; Secretory leukocyte protease inhibitor (slpi) expression downregulates E-cadherin, induces β-catenin re-localization and triggers apoptosis-related events in breast cancer cells; Wiley; Biology Of The Cell; 106; 9; 9-2014; 308-322
dc.identifier0248-4900
dc.identifierhttp://hdl.handle.net/11336/14168
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1854448
dc.description.abstractBACKGROUND INFORMATION: Epithelial cadherin (E-cadherin) is involved in cell–cell adhesion through its extracellular domain, whereas the intracellular domain interacts with adaptor proteins, i.e. β-catenin, links E-cadherin to the actin cytoskeleton and participates in signal transduction events. E-cadherin protects mammary epithelial cells from apoptosis and its loss during tumour progression has been documented. Secretory Leukocyte Protease Inhibitor (SLPI) has anti- and pro-tumourigenic activities but its role in breast cancer has not been fully elucidated. Notwithstanding its relevance, how SLPI affects E-cadherin in breast cancer is still unknown. This study evaluated the effect of SLPI upon E-cadherin/β-catenin expression and apoptosis-related markers in murine (F3II) and human (MCF-7) breast tumour cells either treated with exogenous recombinant human SLPI (rhSLPI) or stably transfected with a plasmid encoding its sequence. RESULTS: Addition of rhSLPI to F3II cells caused a decrease (P < 0.05) in E-cadherin transcript and protein levels. Similar results were observed in SLPI-stable F3II transfectants (2C1), and treatment of 2C1 cells with a siRNA toward SLPI restored E-cadherin to control levels. SLPI-expressing cells showed disruption of E-cadherin/β-catenin complex and increased (P < 0.05) percentage of cells depicting nuclear β-catenin localisation. Associated to these changes, 2C1 cells showed increased Bax/Bcl-2 ratio and p21 protein levels, decreased c-Myc protein levels and decreased Cyclin D1 and Claudin-1 transcript levels. No differences in N- and P-cadherin were observed between SLPI-transfected cells and controls. Addition of rhSLPI to MCF-7 cells or stable transfection with SLPI caused a decrease (P < 0.05) in E-cadherin expression (transcript/protein) and its redistribution to the cytoplasm, as well as β-catenin re-localisation to the cell nucleus. CONCLUSIONS: Expression of SLPI was associated to a decrease in E-cadherin expression and re-localisation of E-cadherin to the cell cytoplasm and β-catenin to the cell cytoplasm and nucleus, and had pro-apoptotic and cell cycle-arrest effects.
dc.languageeng
dc.publisherWiley
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://onlinelibrary.wiley.com/doi/10.1111/boc.201300075/abstract
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1111/boc.201300075
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAPOPTOSIS
dc.subjectBETA-CATENINA
dc.subjectCANCER
dc.subjectCELL ADHESION
dc.subjectEPHITELIAL CADHERIN
dc.subjectSLPI
dc.titleSecretory leukocyte protease inhibitor (slpi) expression downregulates E-cadherin, induces β-catenin re-localization and triggers apoptosis-related events in breast cancer cells
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución